



Supplemental Fig 1: Experimental overview. Human myocardial tissue biopsies from HLHS and TOF patients are sectioned before electrophysiological recordings and force measurements on the same day. Cardiac bodies (CBs) were produced from hiPS derived ventricular cardiomyocytes and cardiac fibroblasts and cultured until experiments. Microelectrode recordings were performed with CBs formed by hanging drop method, while force measurements were carried out with CBs produced by an extracellular matrix (ECM) based approach.





Supplemental Fig 2: Frequency-dependent acceleration of relaxation (FDAR). All groups show FDAR at a stimulation frequency of 3 Hz and 4 Hz as indicated by the reduction in time to 90% relaxation relative to contractions at 2 Hz of individual experiments (HLHS, n = 10 of 6 patients; TOF, n = 19 of 8 patients; 9 wks hiPS-CBs, n = 12; 16 wks hiPS-CBs, n = 5). Lines and error bars represent mean \pm 95% CIs, respectively. Numbers below error bars indicate p-values < 0.05 vs. HLHS (1), TOF (2), 9 wks hiPS-CBs (3), and 16 wks hiPS-CBs (4). 3Hz: ANOVA, $p=5.99 \times 10^{-28}$; Games Howell Post-Hoc: HLHS vs. TOF: $p = 0.004$; HLHS vs. hiPS-CBs 9 wks: $p = 1.29 \times 10^{-10}$; HLHS vs. hiPS-CBs 16 wks: $p = 4.04 \times 10^{-8}$; TOF vs. hiPS-CBs 9 wks: $p = 1.07 \times 10^{-12}$; TOF vs. hiPS-CBs 16 wks: $p = 2.20 \times 10^{-6}$; hiPS-CBs 9 wks vs. hiPS-CBs 16 wks: $p = 0.994$. 4Hz: ANOVA, $p=1.39 \times 10^{-9}$; Games Howell Post-Hoc: HLHS vs. TOF: $p = 0.065$; HLHS vs. hiPS-CBs 9 wks: $p = 1.00 \times 10^{-4}$; HLHS vs. hiPS-CBs 16 wks: $p = 1.15 \times 10^{-3}$; TOF vs. hiPS-CBs 9 wks: $p = 3.99 \times 10^{-10}$; TOF vs. hiPS-CBs 16 wks: $p = 2.24 \times 10^{-4}$; hiPS-CBs 9 wks vs. hiPS-CBs 16 wks: $p = 0.676$.





Supplemental Fig 3: Representative experiments of force-frequency relationships (FFR) pattern. For HLHS and TOF myocardial tissues slices, examples are shown for positive (HLHS6, TOF3), negative (HLHS6, TOF9) and bi-phasic FFRs (HLHS2, TOF4). Because hiPS-CBs did not exhibit diverse FFR patterns, only one representative experiment for 9 wks and 16 wks is depicted. The red traces on the left side show original recordings of

experiments at different stimulation frequencies (1,2,3,4 Hz) and the corresponding averaged twitches are superimposed in the right panels. Note that none of the 16 wks old hiPS-CBs could be stimulated at 1 Hz.



HLHS





TOF



hiPS-CB (9 wks)



hiPS-CB (16 wks)



Supplemental Fig 4: Representative experiments of β -adrenergic stimulation by isoproterenol. Original traces (left panels), averaged twitches (middle panels) and amplitude-normalized averaged twitches (right panels) before and after application of 1 $\mu\text{mol/L}$ isoproterenol (ISO) for myocardial tissues slices from patients HLHS2 and TOF4 as well as hiPS-CBs (9 wks and 16 wks) are depicted. Lusitropic effect of β -adrenergic stimulations is highlighted by amplitude normalisation of the averaged twitches.

Tables:

Table 1: Patients characteristics.

Patient ID	Age (days/months)	Birth weight (g)	Diagnosis ²	Type of operation	Drugs ³	SpO ₂ ⁴	Experiments ⁵
HLHS1	36 / 1.2	3250	HLHSMAS	Norwood procedure	M, D	99	FFR
HLHS2	15 / 0.5	2690	HIAA+VSD	Norwood procedure	M, BB, F, S, D	90	MDA,E4031,FFR, ISO
HLHS3	69 / 2.3	2100	HLHS	Norwood procedure	BB, ASA, D	70	MDA
HLHS4	12 / 0.4	3900	HLHSMMA+TAPVR	Norwood procedure	M, Mil, D	95	MDA,E4031, FFR, ISO
HLHS5	6 / 0.2	2570	HLHSMMAA	Norwood procedure	M	95	MDA, FFR, ISO
HLHS6	7 / 0.2	2800	HLHS	Norwood procedure	M, BB, S, D	95	MDA, FFR, ISO
HLHS7	2 / 0.1	2700	HLHS+MS+AS	Norwood procedure	M, D	90	MDA, FFR, ISO
TOF1	168 / 5.5	3950	TOF+PDA	TOF repair	BB	91	MDA, FFR, ISO
TOF2	170 / 5.6	3000	TOF	TOF repair	Nil	99	MDA,E4031
TOF3	198 / 6.5	3200	TOF	TOF repair	Sot	100	MDA,E4031, FFR, ISO
TOF4	164 / 5.4	3300	TOF	TOF repair	A, S, BB, ASA	72	FFR, ISO
TOF5	210 / 6.9	3850	PA+VSD	VSD closure, RV-PA-conduit	ASA, BB	80	MDA,E4031+ISO, FFR, ISO
TOF6	178 / 5.8	1550	TOF+PDA	TOF repair, closure of PDA	BB	65	MDA,E4031+ISO, FFR, ISO
TOF7	129 / 4.2	3250	TOF	TOF repair	Nil	99	MDA,E4031+ISO, FFR
TOF8	155 / 5.1	3100	TOF	TOF repair	Nil	98	FFR
TOF9	212 / 7.0	2650	PA-VSD	VSD closure, RV-PA-conduit	ASA	75	MDA, FFR
TOF10	165 / 5.5	2900	TOF	TOF repair	Nil	92	E4031

1: M, male; F, female

2: AS, aortic stenosis; IAA, interrupted aortic arch; HLHS, hypoplastic left heart syndrome; PA, pulmonary atresia; PDA, patent ductus arteriosus; TAPVR, total anomalous pulmonary venous return; TOF, Tetralogy of Fallot; VSD, ventricular septal defect

3: A, ACE-inhibitor; ASA, acetylsalicylic acid; BB, β -blocker; D, dexamethasone; F, furosemide ; P, prostaglandin E2; Mil, milrinone; S, spironolactone ; Sot, sotalol

4: Oxyhemoglobin saturation by pulse oximetry

5: FFR, force-frequency-relationship; ISO, isoproterenol; MDA, rate-dependent action potential adaptation.

Supplemental Table 1: AP characteristics.

frequency	Hz	amplitude			MDP			Vmax			APD 20			APD 50			APD 90		
		mean	95% CI	p-value vs. 2 Hz	mean	95% CI	p-value vs. 2 Hz	mean	95% CI	p-value vs. 2 Hz	mean	95% CI	p-value vs. 2 Hz	mean	95% CI	p-value vs. 2 Hz	mean	95% CI	p-value vs. 2 Hz
HUHS																			
1	16	108.6	[104.2, 113.1]	0.017	-81.0	[-85.4, -76.6]	0.029	155.0	[111.8, 198.3]	0.032	126.1	[111.6, 140.5]	1.84 x 10 ⁻⁵	245.2	[225.0, 265.4]	1.59 x 10 ⁻⁷	327.8	[308.8, 346.8]	1.68 x 10 ⁻⁷
2	16	106.3	[102.2, 110.4]	-	-78.1	[-81.7, -74.5]	-	146.0	[110.3, 181.6]	-	105.3	[91.7, 118.8]	-	212.3	[196.5, 228.1]	-	291.4	[278.4, 304.3]	-
3	16	103.5	[98.1, 108.9]	7.21 x 10 ⁻⁷	-76.6	[-79.9, -73.3]	0.11	133.9	[92.0, 175.8]	0.1	83.0	[74.4, 91.7]	1.84 x 10 ⁻⁵	166.3	[155.9, 176.6]	3.00 x 10 ⁻⁵	240.2	[231.2, 249.3]	1.85 x 10 ⁻⁵
TOF																			
1	17	107.9	[103.7, 112.1]	0.82	-81.3	[-85.3, -77.3]	0.81	133.9	[113.7, 154.2]	0.46	135.2	[118.1, 152.3]	4.38 x 10 ⁻⁷	264.5	[203.5, 298.5]	2.23 x 10 ⁻⁵	360.1	[320.6, 399.6]	2.35 x 10 ⁻⁵
2	17	107.4	[102.4, 112.5]	-	-80.0	[-84.4, -75.7]	-	126.1	[102.7, 149.4]	-	119.6	[103.2, 135.9]	-	231.0	[203.0, 259.0]	-	319.0	[287.9, 350.0]	-
3	13	101.1	[94.5, 107.6]	4.21 x 10 ⁻⁵	-75.8	[-81.4, -70.1]	0.15	112.6	[90.7, 134.5]	1.72 x 10 ⁻⁵	93.9	[82.3, 105.5]	3.59 x 10 ⁻⁵	181.9	[163.0, 200.6]	5.75 x 10 ⁻⁷	265.6	[241.0, 290.3]	1.82 x 10 ⁻⁵
iPS-CBs, 9 wks																			
1	9	106.0	[102.1, 109.8]	0.1	-75.1	[-78.3, -72.0]	0.42	90.6	[55.4, 124.8]	0.67	75.0	[70.0, 80.0]	0.38	138.6	[130.1, 147.2]	8.25 x 10 ⁻⁵	189.6	[176.7, 202.5]	0.077
2	17	106.0	[103.1, 108.9]	-	-73.8	[-76.4, -71.2]	-	88.9	[65.2, 112.7]	-	68.8	[64.8, 72.8]	-	123.9	[118.9, 129.0]	-	176.1	[167.8, 184.5]	-
3	12	104.6	[100.7, 108.4]	0.019	-73.9	[-77.7, -70.1]	0.96	80.0	[54.6, 105.3]	0.22	63.9	[59.7, 68.1]	0.086	117.6	[112.3, 123.0]	9.18 x 10 ⁻⁵	170.1	[161.3, 179.0]	0.07
iPS-CBs, 16 wks																			
1	4	96.0	[86.7, 105.4]	0.29	-62.1	[-69.1, -55.1]	0.64	n.a.	n.a.	n.a.	62.4	[55.2, 69.6]	0.26	116.5	[99.2, 133.8]	0.36	173.5	[142.5, 204.6]	0.33
2	10	94.0	[89.9, 98.2]	-	-62.3	[-67.1, -57.5]	-	45.7	[n=2]	-	53.8	[49.2, 58.4]	-	101.3	[93.7, 109.0]	-	149.0	[138.8, 159.3]	-
3	5	95.5	[88.3, 102.7]	0.26	-61.9	[-71.7, -52.1]	0.037	46.5	[21.4, 71.6]	n.a.	51.6	[46.2, 57.0]	0.15	94.2	[85.2, 103.3]	0.22	139.4	[129.1, 149.8]	0.19

RM, ANOVA repeated measures & LSD Post-Hoc testing

FA, Friedman ANOVA & Wilcoxon pairwise testing

1, p-values are computed for RM/FA and individual groups compared to 2Hz

n.a. indicates missing data/lack of post-hoc testing

Supplemental Table 2: Effects of $I_{K,r}$ blockade.

	n	amplitude	MDP	Vmax	APD 50	APD 90	EAD
		mean 95% CI p-value vs. BL (*E4031)	mean 95% CI p-value vs. BL (*E4031)	mean 95% CI p-value vs. BL (*E4031)	mean 95% CI p-value vs. BL (*E4031)	mean 95% CI p-value vs. BL (*E4031)	
		mV mV ms	ms ms ms	mV/s mV/s mV/s	ms ms ms	ms ms ms	
HLHS							
Baseline	3	109.1 [78.5, 139.6]	-80.0 [-96.8, -63.1]	149.4 [-74.4, 373.1]	225.2 [197.1, 253.3]	302.8 [279.8, 325.8]	-
E4031 1µM	3	114.9 [111.7, 118.0]	-85.1 [-97.1, -73.0]	192.3 [88.29, 296.2]	352.4 [252.1, 452.6]	489.9 [342.2, 637.6]	0.032
		0.52	0.75	0.33	0.047		
Fallot							
Baseline	6	108.9 [104.4, 113.4]	-76.5 [-85.9, -66.5]	120.2 [92.2, 148.1]	263.5 [182.2, 344.9]	327.4 [244.1, 410.7]	-
E4031 1µM	6	101.9 [91.9, 112.0]	-71.6 [-82.7, -60.6]	97.7 [85.6, 109.7]	345.0 [259.9, 430.1]	477.6 [365.6, 589.6]	5.53 x 10 ⁻⁴
		0.11	0.23	0.037	1.31 x 10 ⁻³		
IPS-CBs, 9 wks							
Baseline	7	106.2 [102.1, 110.3]	-78.1 [-82.5, -73.7]	96.5 [48.5, 144.5]	124.2 [114.4, 134.0]	176.7 [156.1, 197.3]	-
E4031 1µM	7	106.3 [100.1, 112.5]	-74.6 [-77.6, -71.7]	68.2 [33.3, 103.1]	146.1 [133.9, 158.2]	248.5 [225.2, 271.8]	3.51 x 10 ⁻³
		0.97	0.28	0.21	6.46 x 10 ⁻³		
Fallot							
Baseline	7	104.4 [98.7, 110.7]	-75.1 [-78.6, -71.52]	128.1 [95.1, 161.0]	220.6 [193.2, 247.9]	335.8 [308.4, 363.3]	-
E4031 0.1µM	7	100.9 [91.4, 110.3]	-74.1 [-78.3, -69.9]	78.7 [62.7, 94.7]	293.7 [252.9, 334.5]	511.9 [442.7, 581.0]	2.15 x 10 ⁻¹
+isoproterenol	5	110.1 [104.5, 115.8]	-81.0 [-85.9, -76.2]	56.2 [n.a.]	270.0 [190.3, 349.7]	463.4 [291.4, 635.4]	0.38*
		0.23*	6.56 x 10 ^{-3*}	n.a.	0.27*		
IPS-CBs, 9 wks							
Baseline	8	105.5 [98.7, 112.3]	-74.2 [-77.2, -71.1]	86.5 [47.4, 125.7]	122.1 [115.3, 128.8]	168.5 [162.5, 174.5]	-
E4031 0.1µM	8	110.8 [106.8, 114.7]	-73.4 [-97.5, -49.2]	98.2 [75.2, 121.3]	130.0 [121.9, 138.1]	213.0 [195.3, 230.7]	3.14 x 10 ⁻¹
+isoproterenol	7	110.7 [106.3, 115.1]	-75.5 [-86.2, -64.8]	87.6 [70.3, 104.9]	111.3 [80.2, 142.5]	191.8 [152.5, 231.0]	0.40*
		0.26*	0.97*	0.49*	0.18*		
IPS-CBs, 16 wks							
Baseline	6	95.3 [86.7, 103.9]	-70.4 [-75.2, -65.6]	18.0 [3.1, 33.0]	106.2 [84.5, 127.9]	148.1 [117.8, 178.3]	-
E4031 0.1µM	5	97.0 [89.6, 104.4]	-67.2 [-92.1, -42.3]	14.4 [11.9, 16.9]	133.3 [115.4, 151.2]	239.0 [219.5, 258.6]	0.048
+isoproterenol	4	91.9 [84.8, 98.9]	-60.2 [-80.3, -40.2]	16.6 [9.9, 23.4]	101.0 [64.2, 137.7]	181.7 [126.3, 237.1]	0.042*
		0.83*	0.43*	0.45*	0.17*		

BL, baseline

RM, ANOVA repeated measures & LSD Post-Hoc testing

FA, Friedman ANOVA & Wilcoxon pairwise testing

1, p-values are computed for RM/FA and individual groups compared to baseline or E4031
(*)

n.a. indicates missing data/lack of post-hoc testing

Supplemental Table 3: Force Frequency Relationship (FFR).

		time to peak			time to 50% relaxation			time to 90% relaxation			
	Hz	n	mean	95% CI	p-value ¹	mean	95% CI	p-value ¹	mean	95% CI	p-value ¹
			ms	ms	vs. 2 Hz	ms	ms	vs. 2 Hz	ms	ms	vs. 2 Hz
HLHS	0.5	9	226.7	[205, 248]	3.91×10^{-3}	348.2	[323, 374]	3.91×10^{-3}	475.2	[433, 518]	3.49×10^{-3}
	1	10	208.7	[191, 227]	3.91×10^{-3}	310.4	[285, 336]	3.91×10^{-3}	436.7	[400, 474]	9.63×10^{-4}
	1.5	10	196.5	[184, 209]	1.95×10^{-3}	299.4	[260, 291]	1.95×10^{-3}	417.9	[391, 445]	1.60×10^{-4}
	2	10	182.2	[172, 193]	-	275.3	[260, 291]	-	377.8	[359, 397]	-
	1.5	10	162.8	[153, 173]	1.95×10^{-3}	241.6	[228, 255]	1.95×10^{-3}	317.7	[303, 333]	3.49×10^{-3}
	3	10	166.9	[154, 180]	1.95×10^{-3}	249.1	[231, 268]	1.95×10^{-3}	330.1	[309, 351]	1.25×10^{-3}
	4	10	143.0	[133, 153]	1.95×10^{-3}	208.1	[197, 220]	1.95×10^{-3}	260.3	[252, 268]	9.81×10^{-8}
						RM: 7.61×10^{-13}					
						FA: 1.67×10^{-23}					
						RM: 9.90×10^{-11}					
TOF	0.5	19	259.3	[245, 274]	2.68×10^{-10}	401.1	[387, 415]	2.48×10^{-17}	552.4	[539, 566]	7.41×10^{-15}
	1	19	240.1	[230, 251]	2.25×10^{-10}	368.1	[357, 379]	1.29×10^{-11}	514.2	[502, 527]	2.43×10^{-14}
	1.5	19	224.2	[216, 232]	5.78×10^{-11}	345.1	[336, 354]	2.21×10^{-11}	482.3	[471, 494]	6.64×10^{-14}
	2	19	204.5	[197, 212]	-	314.6	[307, 323]	-	423.7	[415, 433]	-
	1.5	19	186.9	[181, 193]	5.33×10^{-8}	286.2	[279, 293]	5.48×10^{-11}	374.4	[368, 381]	1.46×10^{-15}
	3	19	172.8	[167, 179]	5.55×10^{-10}	261.7	[255, 268]	2.82×10^{-15}	331.5	[326, 337]	1.31×10^{-16}
	4	17	153.7	[148, 159]	5.27×10^{-11}	224.1	[218, 231]	9.72×10^{-15}	271.5	[267, 276]	1.03×10^{-18}
						RM: 4.72×10^{-22}					
						FA: 1.67×10^{-23}					
						RM: 1.09×10^{-30}					
hiPS-CBs, 9 wks	0.5	2	n.a.	n.a.	0.090	n.a.	n.a.	2.61×10^{-5}	n.a.	n.a.	2.56×10^{-3}
	1	6	143.8	[130, 158]	0.16	228.2	[209, 248]	0.031	300.3	[273, 327]	1.0
	1.5	8	147.0	[138, 156]	0.27	227.0	[215, 239]	0.079	289.4	[274, 304]	0.045
	2	12	140.6	[135, 146]	-	218.3	[210, 227]	-	280.2	[267, 293]	-
	1.5	12	137.3	[132, 143]	0.13	209.3	[201, 217]	0.17	266.7	[255, 278]	0.80
	3	12	140.6	[132, 149]	0.5	212.8	[205, 221]	0.23	272.8	[263, 283]	0.50
	4	11	136.1	[131, 141]	0.5	199.0	[191, 207]	0.084	249.5	[239, 260]	0.028
						RM: 1.83×10^{-3}					
						FA: 1.67×10^{-23}					
						RM: 2.56×10^{-3}					
hiPS-CBs, 16 wks	0.5	0	n.a.	n.a.	n.a.	n.a.	n.a.	2.954×10^{-4}	n.a.	n.a.	6.84×10^{-08}
	1	0	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
	1.5	0	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
	2	5	142.6	[134, 151]	-	218.6	[206, 231]	-	270.6	[258, 284]	-
	1.5	5	136.8	[130, 144]	0.040	206.0	[196, 216]	4.55×10^{-3}	253.0	[241, 265]	2.77×10^{-3}
	3	5	139.6	[134, 145]	1.92×10^{-3}	211.2	[200, 223]	3.33×10^{-3}	259.6	[248, 271]	5.73×10^{-3}
4	5	133.2	[127, 140]	7.99×10^{-4}	195.8	[187, 205]	5.09×10^{-4}	240.0	[231, 249]	4.41×10^{-4}	

RM, ANOVA repeated measures & LSD Post-Hoc testing

FA, Friedman ANOVA & Wilcoxon pairwise testing

1, p-values are computed for RM/FA and individual groups compared to 2Hz

n.a. indicates missing data/lack of post-hoc testing

Supplemental Table 4: Effect of β -adrenergic stimulation on twitch morphology.

		Relative force (change to BL)			time to peak			time to 50% relaxation			time to 90% relaxation				
		mean	95% CI	p-value ¹ vs. 10 ⁻¹⁰ mol/L	mean	95% CI	p-value ¹ vs. BL	mean	95% CI	p-value ¹ vs. BL	mean	95% CI	p-value ¹ vs. BL		
		%	%		ms	ms		ms	ms		ms	ms			
HLHS	mol/L	n													
	BL	6	0	[0, 0]	RM: 5.24 x 10 ⁻⁵	185	[165, 205]	RM: 7.37 x 10 ⁻¹⁰	278	[246, 309]	FA: 1.95 x 10 ⁻⁸	374	[341, 407]	FA: 2.55 x 10 ⁻⁸	
	10 ⁻¹⁰	5	-9	[-17, -1]	-	185	[160, 210]	0.32	280	[239, 320]	-	180	[331, 420]	0.81	
	10 ⁻⁹	6	-12	[-24, -1]	0.44	180	[163, 197]	0.069	273	[247, 300]	0.14	372	[343, 401]	0.53	
	10 ⁻⁸	6	-12	[-131, 107]	0.34	166	[143, 188]	0.049	246	[218, 275]	0.028	338	[308, 368]	0.031	
	10 ⁻⁷	6	159	[23, 296]	0.052	151	[125, 178]	3.93 x 10 ⁻³	222	[184, 260]	0.028	294	[244, 344]	0.031	
	10 ⁻⁶	6	403	[99, 707]	0.032	149	[132, 166]	7.38 x 10 ⁻⁴	218	[192, 243]	0.027	285	[252, 318]	0.031	
	10 ⁻⁵	6	478	[129, 826]	0.028	150	[134, 166]	2.25 x 10 ⁻³	220	[199, 241]	0.028	283	[257, 309]	0.031	
	TOF	BL	11	0	[0, 0]	FA: 4.46 x 10 ⁻⁴	201	[188, 214]	RM: 4.63 x 10 ⁻³	303	[286, 320]	RM: 2.10 x 10 ⁻⁴	406	[388, 425]	RM: 7.09 x 10 ⁻⁵
		10 ⁻¹⁰	10	5	[-9, 19]	-	199	[184, 214]	0.64	299	[279, 319]	-	402	[378, 425]	1.00
10 ⁻⁹		11	44	[-26, 113]	0.63	192	[174, 210]	1.00	286	[256, 312]	0.30	383	[348, 419]	0.17	
10 ⁻⁸		11	122	[12, 233]	0.38	176	[160, 192]	0.15	264	[241, 288]	0.13	356	[318, 394]	0.27	
10 ⁻⁷		11	216	[118, 314]	3.91 x 10 ⁻³	164	[156, 172]	0.077	247	[232, 262]	0.096	328	[302, 354]	0.077	
10 ⁻⁶		11	378	[199, 557]	1.95 x 10 ⁻³	155	[148, 162]	0.049	231	[218, 245]	0.063	307	[291, 322]	0.039	
10 ⁻⁵		3	336	[-401, 1072]	0.25	154	[131, 176]	0.048	230	[201, 259]	0.076	312	[284, 341]	0.061	
hiPS-CBs, 9 wks		BL	5	0	[0, 0]	FA: 9.03 x 10 ⁻⁴	141	[127, 155]	RM: 3.68 x 10 ⁻⁸	223	[194, 251]	RM: 2.09 x 10 ⁻⁶	288	[245, 331]	RM: 7.38 x 10 ⁻⁶
		10 ⁻¹⁰	5	-1	[-8, 7]	-	139	[125, 153]	0.16	223	[199, 247]	0.93	292	[253, 330]	0.57
		10 ⁻⁹	5	-2	[-13, 9]	0.63	140	[125, 156]	0.21	221	[197, 246]	0.35	286	[250, 322]	0.50
	10 ⁻⁸	5	-7	[-19, 6]	0.13	139	[124, 154]	0.12	221	[195, 247]	0.12	285	[248, 322]	0.29	
	10 ⁻⁷	5	-15	[-22, -9]	0.063	136	[123, 150]	0.013	217	[194, 240]	0.18	281	[247, 316]	0.20	
	10 ⁻⁶	5	-17	[-27, -6]	0.063	127	[118, 137]	7.09 x 10 ⁻³	201	[187, 216]	0.025	263	[237, 289]	0.030	
	10 ⁻⁵	5	-21	[-36, -5]	0.063	124	[112, 135]	4.35 x 10 ⁻³	196	[178, 215]	0.030	255	[231, 280]	0.038	
	hiPS-CBs, 16 wks	BL	5	0	[0, 0]	RM: 0.49	134	[130, 138]	FA: 6.29 x 10 ⁻³	200	[192, 208]	RM: 1.64 x 10 ⁻⁴	248	[240, 257]	RM: 2.15 x 10 ⁻⁴
		10 ⁻¹⁰	5	-2	[-4, -1]	-	134	[131, 194]	1.0	201	[194, 207]	-	249	[242, 255]	-
		10 ⁻⁹	5	-4	[-6, -2]	n.a.	134	[131, 136]	1.0	199	[193, 206]	0.76	247	[240, 255]	0.90
10 ⁻⁸		5	-4	[-7, -1]	n.a.	132	[124, 139]	0.75	197	[185, 209]	0.56	244	[229, 260]	0.58	
10 ⁻⁷		5	-3	[-11, 4]	n.a.	129	[119, 139]	0.5	192	[178, 207]	0.32	240	[223, 257]	0.33	
10 ⁻⁶		5	1	[-13, 14]	n.a.	122	[112, 132]	0.13	183	[169, 197]	0.035	229	[213, 245]	0.032	
10 ⁻⁵	5	2	[-14, 17]	n.a.	120	[110, 129]	0.063	181	[168, 194]	0.026	227	[213, 242]	0.025		

BL, baseline

RM, ANOVA repeated measures & LSD Post-Hoc testing

FA, Friedman ANOVA & Wilcoxon pairwise testing

1, p-values are computed for RM/FA and individual groups compared to baseline

n.a. indicates missing data/lack of post-hoc testing